A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
BACKGROUND: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically rele...
Uloženo v:
| Vydáno v: | J Transl Med |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415560/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15050026/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/1479-5876-2-9 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
